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Abstract: The integrity of bone tissue and its remodeling that occurs throughout life requires 
a coordinated activity of osteoblasts and osteoclasts. The decreased estrogen circulating level 
during postmenopausal transition, with a prevalence of osteoclastic activity over osteoblastic 
activity, represents the main cause of bone loss and osteoporosis. Osteoporosis is a chronic 
disease requiring long-term therapy and it is important to evaluate the efﬁ  cacy and safety of 
treatments over several years, as the fear of health risks is a common reason for discontinuing 
therapy. Raloxifene is a selective estrogen receptor modulator (SERM) leading to estrogen-
agonist effects in some tissues and estrogen-antagonist effects in others. Raloxifene is effective 
to prevent and treat postmenopausal vertebral osteoporosis, with reduction of spine fractures 
and, in post-hoc analyses, non-spine fractures in high-risk subjects. Moreover, raloxifene 
reduces the risk of invasive breast cancer and improves the levels of serum lipoprotein but with 
an increased risk of venous thromboembolism and fatal stroke, without signiﬁ  cant change in 
the incidence of coronary events. For these reasons the overall risk-beneﬁ  t proﬁ  le is favorable. 
Therefore, when considering the use of raloxifene in a postmenopausal woman, we should take 
into account the osteoporosis-related individual risk and weigh the potential beneﬁ  ts, skeletal 
and extra-skeletal, against the health risks.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-
architectural deterioration of bone tissue, with a consequent decrease in bone mineral 
density (BMD) and increase in bone fragility and susceptibility to fracture.1
The decreased estrogen circulating level during postmenopausal age represents the 
main cause of bone loss and osteoporosis2,3 and about 54% of women age 50 years or 
older will have an osteoporotic fracture during their lifetime.4 A rapid decrease of bone 
mass is evident in the ﬁ  rst 5 to 10 years following the menopause and the annual rate 
of bone loss is at a maximum of about 4% during the former 4 years,5 then declines 
to 1%.6 In this period, the physiological bone remodeling is characterized mainly by 
a relevant prevalence of the resorption due to osteoclastic activity.7
Osteoporosis and osteoporosis-related fractures are a relevant and increasing problem 
for public health: in the year 2000, there were estimated to be 620,000 new fractures 
at the hip, 574,000 at the forearm, 250,000 at the proximal humerus and 620,000 clini-
cal spine fractures in men and women aged 50 years or over in Europe.8 Osteoporotic 
fractures also occur at many other sites including the pelvis, ribs, and distal femur and 
tibia and, collectively, all osteoporotic fractures account for 2.7 million fractures in 
men and women in Europe at a direct cost of  36 billion.9 Moreover, elderly people 
represent the fastest growing age group and with an aging population the incidence of International Journal of Women’s Health 2009:1 12
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hip fractures is likely to rise substantially: it is predicted that 
the estimated number of hip fractures worldwide will rise 
from 1.7 million in 1990 to 6.3 million in 2050.10
The increasing prevalence and cost of osteoporosis 
have heightened interest in the efﬁ  cacy and safety of agents 
available to treat the bone loss associated with osteoporosis. 
During the last 20 years, many drugs have been granted a 
marketing license for treatment of osteoporosis. Bisphos-
phonates are the most widely prescribed drugs: alendronate 
and risedronate are given daily or weekly and have demon-
strated efﬁ  cacy on reduction of fracture rates at the spine 
and hip; ibandronate has demonstrated spine antifracture 
efﬁ  cacy with intervals between doses greater than weekly. 
Strontium ranelate is suggested to be the ﬁ  rst medication to 
uncouple bone formation from bone resorption and it has 
shown antifracture efﬁ  cacy at all sites in a large number of 
postmenopausal women. The selective estrogen-receptor 
modulator (SERM) raloxifene reduces spine fractures and 
non-spine fractures in high-risk subjects in post-hoc analyses 
with extra-skeletal beneﬁ  ts (such as in the breast).11
Osteoporosis is a chronic disease requiring long-term 
therapy; thus it is important to evaluate the efﬁ  cacy and safety 
of therapies over several years. In fact, despite treatment 
options that can reduce the risk of fracture in patients with 
osteoporosis, few patients fully adhere to current therapies 
and the fear of health risks is a commonly cited reason 
for discontinuing therapy: a recent study reported 1-year 
adherence rates of less than 25% for all osteoporosis therapies 
examined.12
The aim of this review is to analyze the long term safety 
and efﬁ  cacy of the second-generation SERM raloxifene, the 
only drug approved worldwide for the prevention and treat-
ment of postmenopausal osteoporosis. In particular, raloxifene 
60 mg/day oral dosage was approved by the US Food and 
Drug Administration (FDA) for postmenopausal osteoporosis 
prevention in 1997 and postmenopausal osteoporosis treatment 
in 1999; until 2006 over 50,000 women have participated in 
clinical trials with this drug and over 40 million prescriptions 
for raloxifene have been written worldwide.13 In a search of 
Medline (www.pubmed.gov) through December 2008 for 
“raloxifene” we found 2322 items (1889 items on human-
only studies).
Mechanism of action
The integrity of the skeleton and the bone remodeling that 
occurs throughout life requires the coordinated regulation and 
activity of osteoblasts and osteoclasts. The number of active 
osteoclasts is determined by the net result of differentiation 
and fusion of osteoclast precursors and by the loss of 
osteoclasts through apoptosis. An increase in active osteoclast 
pool size, with increased bone resorption and decreased 
bone mass, occurs in many osteopathic disorders, including 
postmenopausal osteoporosis.
Estrogens act on bone with two activities:14 one directly 
mediated by the estrogen receptors (ER) present on the bone 
cell,15 the other, indirect and delayed, that acts through a 
change of calcium metabolism at the level of the intestine, 
kidneys and parathyroids.16 Estrogen deﬁ  ciency determines 
an inhibition of mature osteoblasts and osteocytes, while it 
promotes faster osteoblastic apoptosis.17
In the last few years, many studies have been published 
focusing the attention of the media on possible side effects 
of hormone replacement therapy on the breast and the cardio-
vascular system.18–20 Consequently, more data have been pro-
vided in patients with osteoporosis by the use of  SERMs, of 
which raloxifene was the ﬁ  rst to be validated in the reduction 
of vertebral fractures in osteoporotic menopausal women.21,22
Unlike estrogens, which are pure agonists, and 
anti-estrogens, which are pure or selective antagonists, 
raloxifene exerts selective agonist or antagonist effects on 
various estrogen target tissues.
The mechanisms of the tissue-selective, mixed agonist-
antagonist action of SERMs, although still only partly 
understood, are gradually becoming clearer.23 Most of 
the pharmacology of SERMs can be explained by three 
interactive mechanisms: differential ER expression in a 
given target tissue, differential ER conformation on ligand 
binding, and differential expression and binding to the ER 
of coregulator proteins.24
In particular, raloxifene binds to the ER, leading to 
estrogen-agonist effects in some targets (bone and lipid 
metabolism) and estrogen-antagonist effects in others (breast 
and endometrium).25 Raloxifene has anti-estrogenic effects 
in the breast, competitively blocking estrogen-induced 
DNA transcription26 and inhibiting the growth of estrogen-
stimulated mammary cancers in animals.27
Raloxifene plays an analogous role to estrogens on bone 
tissue, but its osteoblastic actions remain to be fully clariﬁ  ed. 
In in vitro studies raloxifene modulates the bone homeostasis 
inhibiting osteoclastogenesis and the bone resorption with 
dose-dependent activity.28 This is a complex mechanism that 
implies direct and indirect activities on bone cells16,28 and a 
down-regulation of the osteoblastic production of IL-6 and 
other cytokines.28–30
New hypotheses on management of osteoporosis have 
arisen from the recent discovery of a cytokine pathway that International Journal of Women’s Health 2009:1 13
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regulates osteoclastogenesis and modulates osteoclastic 
bone resorption: the OPG/RANK/RANKL system.31,32 
Osteoprotegerin (OPG) is a protein expressed by osteoblasts 
that, linking the receptor activator of nuclear factor κB 
(RANK) ligand (RANKL), blocks the process of osteoclastic 
differentiation and modulates osteoclastic apoptosis.32–34 
The binding of RANKL to RANK on osteoclasts initiates 
a cascade of intracellular signaling events35 and OPG, 
acting as a decoy receptor for RANKL, blocks the process 
of osteoclast differentiation and modulates apoptosis.29,36 
OPG is a negative regulator of osteoclast mediated bone 
resorption37 and when RANKL overwhelms OPG, bone 
resorption can become excessive leading to osteoporosis; 
therefore, a healthy skeleton could depend on a balanced 
RANKL/OPG ratio.38 Raloxifene stimulates the production 
of OPG from osteoblasts, as demonstrated in vitro28,29,39 and 
in vivo,30 carrying out their antiresorption activity, at least 
in part, as a means of the OPG/RANK/RANKL system, and 
it could improve osteoporosis, also through an increase of 
OPG production by osteoblasts.
Therefore, raloxifene was associated with a statistically 
highly signiﬁ  cant suppression of bone resorption markers 
osteocalcin (−26.3%) and urinary cross-linked N-telopeptides 
of type I collagen (NTX) (−34%),40 and both newly 
synthesized (ααCTX) and mature (ββCTX) collagen type I 
degradation.41
Efﬁ  cacy
In the ﬁ  rst “over 1000 participants” raloxifene trial, in 1145 
healthy postmenopausal women aged 45 through 60 years 
the lumbar spine BMD increased from baseline to 36 months 
by 1.28 ± 0.23%. Comparable BMD changes were observed 
in the hip and total body.42
By clinical trials on efﬁ  cacy of raloxifene, the Multiple 
Outcomes Raloxifene Evaluation (MORE) study was designed 
to test whether raloxifene reduced the risk for fracture in 
postmenopausal women with osteoporosis. From 1994 to 
1998, 7705 postmenopausal women with osteoporosis (mean 
age 66.5) were randomized to receive 60 mg raloxifene, 120 
mg raloxifene, or placebo (mainly in the United States and 
Europe). At 36 months of follow-up, the risk for vertebral 
fracture was reduced 30% in women with a vertebral fracture 
and 55% in women without prevalent fractures over 3 years. 
Moreover, the BMD gains after 3 years were 2.1% in the 
spine and 2.6% in the femur, while BMD gains after 4 years 
were 2.6% in the spine and 2.1% in the femur with a 50% 
reduction in the fourth year versus a 55% reduction in years 
0 to 3 (BMD increases were signiﬁ  cant during the third year, 
but not during the fourth year).40,43 In this trial, raloxifene 
not only shows beneﬁ  ts in the absolute reduction of the 
risk of vertebral fractures, but also ameliorates the severity 
of future vertebral fracture21 and can decrease the absolute 
number of vertebral fractures.44 Moreover, raloxifene showed 
a fast-acting efﬁ  cacy on reduction of vertebral fracture 
(–68%, p = 0.01, in a 1-year post hoc analysis; –90%, p = 
0.01, in a 6-month post hoc analysis; –80%, p = 0.034, in a 
3-month post hoc analysis).45,46
The Continuing Outcomes Relevant to Evista (CORE) 
trial examined the effect of an additional 4 years of raloxifene 
therapy on the incidence of invasive breast cancer (primary 
endpoint) in women in the MORE trial who agreed to 
continue therapy (4011 women with a mean age of 65.8). 
In this population BMD was higher in the raloxifene group 
than in the placebo group, by 2.2% in the spine and 3% in 
the total hip (p  0.01).47
Also the Raloxifene Use for The Heart (RUTH) trial, 
that evaluated as primary endpoint the effect of raloxifene 
on cardiovascular events in 10,101 postmenopausal women 
for a median of 5.6 years (mean age 67.5 years), clearly 
demonstrates the beneﬁ  ts of raloxifene in older women in the 
prevention of clinical vertebral fracture (–35%, p = 0.007), 
but not for nonvertebral fractures (p  0.05 versus placebo), 
irrespective of presence or absence of risk factors for 
fracture.48,49
The Evista Versus Alendronate (EVA) trial is the ﬁ  rst 
head-to-head trial with fracture as a primary endpoint; it is a 
multicenter, double-blind, double-dummy, randomized trial 
with two active treatment arms. This trial compares directly 
the osteoporotic fracture risk reduction efﬁ  cacy of raloxifene 
and alendronate in 1412 postmenopausal women with osteo-
porosis (mean age of 66 years). The EVA trial showed that 
raloxifene decreases the incidence of osteoporosis-associated 
fractures.50 Although women treated with alendronate showed 
a greater BMD increase compared with raloxifene use, no 
statistical difference in the fracture risks between alendronate 
and raloxifene was found. Lumbar spine, femoral neck, and 
total hip BMD were increased from baseline at 2 years in 
each group (p  0.001) suggesting that both drugs serve 
equally as effectively, if our purpose was only the prevention 
of fracture.51 In addition, superiority in the prevention of 
fractures has not been shown for any bisphosphonate class 
agent and superiority for the prevention of vertebral fractures 
has not been demonstrated for bisphosphonates compared 
with calcitonin, calcium, or raloxifene.52 On the contrary, 
a recent study showed an efﬁ  cacy of alendronate greater 
than raloxifene in increasing lumbar BMD and a marked International Journal of Women’s Health 2009:1 14
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reduction of   bone turnover compared with raloxifene in 
elderly women with osteoporosis.53
In the prevention trials, fewer women in the raloxifene 
treatment group progressed from normal to osteopenia and 
from osteopenia to osteoporosis. In fact, 5 years of raloxifene 
treatment in healthy postmenopausal women preserved BMD 
and signiﬁ  cantly reduces the likelihood of development of 
osteoporosis.54 On the contrary, raloxifene discontinuation 
after 5 years was followed by signiﬁ  cant declines in BMD at 
the lumbar spine and femur (–2.4%) within the ﬁ  rst year.55 
However, no data are available on the fracture risk after 
raloxifene discontinuation.56
The risk reduction for non-vertebral fractures in the 
overall MORE population was not significant, but a 
reduction of 47% (p = 0.04) was noted in a post hoc analy-
sis of patients with severe prevalent vertebral fractures.44 
However, even if raloxifene does not inﬂ  uence periosteal 
apposition in the proximal femur, it produces small but 
signiﬁ  cant improvement in resistance to axial and bending 
stresses.57
In the CORE trial, the risk of at least one new 
non-vertebral fracture was similar in the placebo (22.9%) 
and raloxifene (22.8%) groups (hazard ratio [HR] 1.0).47 The 
incidence of at least one new non-vertebral fracture at six 
major sites (clavicle, humerus, wrist, pelvis, hip, and lower 
leg) was 17.5% in both groups. Post hoc Poisson analyses, 
which account for multiple events, showed no overall effect 
on non-vertebral fracture risk; however, a decreased risk 
(−22%) was found at six major non-vertebral sites in women 
with prevalent vertebral fractures (HR 0.78, p = 0.017) and 
with severe vertebral fractures (HR 0.64, p  0.05).47 The 
RUTH trial also showed that raloxifene was not sufﬁ  cient 
for preventing non-vertebral fractures, because there was no 
difference in non-vertebral fractures between the raloxifene 
treatment and placebo groups.48,49 One explanation for 
this apparent absence of a non-vertebral effect is that the 
weaker antiresorptive effects of raloxifene can return high 
bone turnover to normal and prevent micro-architectural 
deterioration in trabecular bone, but the reduction of fracture 
risk at sites of cortical bone, such as the hip, requires more 
potent antiresorptive effects.23
In a study on 1051 non-vertebral fractures observed 
within 12 months, no large differences in fracture risk were 
found between risedronate (HR 1.01) or raloxifene (HR 
1.18) and alendronate. However, among those with a fracture 
history, raloxifene recipients experienced more non-vertebral 
fractures within 12 months (HR 1.78) compared with 
alendronate recipients.58
Recently a 3-year open-label comparative study on 90 
postmenopausal women has shown that raloxifene plus 
ossein-hydroxyapatite compound appears to be more effective 
in controlling bone loss than raloxifene plus calcium carbonate 
for the control of bone loss in postmenopausal women.59
Safety
Endometrium
Raloxifene differs from tamoxifen, a ﬁ  rst-generation SERM, 
principally by its lack of stimulation of the endometrium.60 
No increase in the risk for endometrial cancer was observed 
in the CORE trial: there was no difference in the incidence of 
uterine cancer, endometrial hyperplasia, or postmenopausal 
bleeding between the raloxifene and placebo treatment 
groups (p  0.5)47,61,62
In the Study of Tamoxifen and Raloxifene (STAR), a 
1999–2004 prospective, double-blinded, randomized clinical 
trial on 19,747 postmenopausal women (mean age 
58.5 years), raloxifene did not show the same effect on the 
uterus as tamoxifen (endometrial cancer relative risk [RR] 
0.62, endometrial hyperplasia RR 0.16).63,64
In another study, 5 years’ raloxifene treatment in 
healthy postmenopausal women was not associated with 
an increased rate of vaginal bleeding, endometrial hyper-
plasia, or endometrial carcinoma, compared with placebo: 
similar incidence of vaginal bleeding (p = 0.999) or of 
mean endometrial thickness of more than 5 mm at baseline 
and at each visit, up to the 5-year endpoint (p  0.349); no 
diagnoses of endometrial hyperplasia or endometrial cancer 
were made.54
Breast
Raloxifene has anti-estrogenic effects in the breast, 
competitively blocking estrogen-induced DNA transcription27 
and inhibiting the growth of estrogen-stimulated mammary 
cancers in animals.27 Moreover, raloxifene reduces mam-
mographic breast density64 and breast cancer proliferative 
indices66 and plays a protective role in decreasing the inci-
dence of breast cancer.
The MORE trial showed a breast cancers risk reduction 
of 65% (RR 0.35) and 76% (RR 0.24) among the patients 
with invasive cancer. The risk reduction was limited to 
ER-positive tumors (RR 0.10), with no decrease occurring 
in ER-negative tumors (RR 0.88).67 Continued follow-up of 
MORE participants showed an ongoing breast cancer risk 
reduction in postmenopausal women treated with raloxifene: 
the risk reduction was 72% (RR 0.28) and 84% (RR 0.16) of 
the ER-positive breast cancers.68International Journal of Women’s Health 2009:1 15
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In the CORE trial that examined the effect of an additional 
4 years of raloxifene therapy in women in the MORE trial 
who agreed to continue therapy, the primary endpoint was 
the incidence of invasive breast cancer; a secondary objective 
looked at the incidence of ER-positive invasive breast 
cancers: the risk for invasive breast cancer was reduced by 
59% (HR 0.41) in the raloxifene group compared with the 
placebo group, and the incidence of ER-positive invasive 
breast cancer by 66% (HR 0.34). However, for the prevention 
of either invasive ER-negative breast cancer or non-invasive 
breast cancer, the effect of raloxifene seemed to be uncertain, 
since no statistical difference was noted between the 
treatment group and the placebo group (HR 1.13, p = 0.86 
and HR 1.78, p = 0.47 respectively). Collectively, during the 
8 years of the MORE and CORE trials, a 66% reduction in the 
incidence of invasive breast cancer with raloxifene versus a 
placebo was noted (HR 0.34, p  0.001).61,62 In addition, in a 
post hoc analysis of postmenopausal women participating in 
MORE and CORE, raloxifene treatment reduced the risk of 
invasive and invasive ER-positive breast cancers in women 
with low bone mass and those with osteoporosis.69
The STAR trial on 19,747 postmenopausal women at 
least 35 years old and with increased risk for developing 
breast cancer (mean age 58.5 years), indicated with that 
raloxifene is as effective as tamoxifen in reducing the risk 
of invasive breast cancer among women at increased risk. 
In this trial, at 60 mg/day versus tamoxifen 20 mg/day over 
5 years, raloxifene was found to be as effective as tamoxifen 
in postmenopausal Caucasian women at increased risk for 
invasive breast cancer (RR 1.02), and, although it does not 
reduce the risk for noninvasive breast cancer like tamoxifen 
(RR 1.40), it has fewer risks of uterine cancers and venous 
thromboembolic events.63,64
Also the RUTH trial evaluated the effect of raloxifene on 
invasive breast cancer risk in 10,101 postmenopausal women 
(mean age, 67.5 years) for a median of 5.6 years: as compared 
with placebo, raloxifene reduced the risk of invasive breast 
cancer by 44% (HR 0.56, p = 0.003); the beneﬁ  t was primarily 
due to a reduced risk of ER-positive invasive breast cancers 
by 55% (HR 0.45). No signiﬁ  cant difference was seen in ER-
negative invasive breast cancers between the groups.48,70
Heart
The MORE trial showed no signiﬁ  cant overall effect of 
raloxifene on cardiovascular events but suggested a reduced 
risk among women who were at increased risk for cardiovas-
cular events.71 Also in the CORE trial, there was no difference 
in the incidence of myocardial infarction.62
The RUTH trial evaluated for a median of 5.6 years the 
effect of raloxifene on cardiovascular events in postmeno-
pausal women with coronary heart disease, peripheral arterial 
disease, or multiple risk factors for coronary heart disease 
(mean age, 67.5 years). The outcome was coronary events 
(ie, death from coronary causes, myocardial infarction, 
or hospitalization for an acute coronary syndrome), and 
compared with placebo, raloxifene had no signiﬁ  cant effect 
on the risk of primary coronary events (HR 0.95).48
On the contrary, raloxifene therapy has been associated 
with improvement in the levels of serum lipoprotein 
cholesterol,60 ﬁ  brinogen72 and homocysteine.73 During a 
3-year experience, raloxifene signiﬁ  cantly reduced total 
cholesterol (−5.5%, p  0.001) and low-density lipoprotein 
cholesterol (−8.7%, p  0.001) compared with placebo. No 
signiﬁ  cant changes in high-density lipoprotein cholesterol 
(p = 0.257) or triglycerides (p = 0.620) were detected,54 while 
in a subgroup of women with high triglycerides raloxifene 
treatment gave an equal or more robust reduction in lipid 
and lipoprotein parameters.74 In addition, raloxifene may 
improve platelet metabolism in healthy postmenopausal 
women through an increase in the bioavailability of platelet 
NO and the beneﬁ  cial effects on lipid metabolism.75
The favorable effect of raloxifene on markers of 
cardiovascular risk was coupled with evidence from 
observational studies that treatment with estrogen was 
associated with a reduced risk of coronary heart disease in 
postmenopausal women.76,77 In fact, also in large trials, there 
was no difference in the incidence of myocardial infarction 
and ischemic heart disease events between the raloxifene 
and placebo or tamoxifen treatment groups (p  0.5).62–64 
Moreover, raloxifene slowed down the progression of intima-
media thickness in postmenopausal women.78
Venous system
Many studies found that raloxifene use was associated with 
an increased risk of venous thromboembolic events.20,79,80
In the MORE and CORE trials the women had an increased 
risk for venous thromboembolic events, both deep vein throm-
bosis and pulmonary embolus, compared with those assigned 
to placebo (RR 3.1 and 2.17 respectively).40,43,61 The risk of 
venous thromboembolism plus pulmonary embolism due to 
raloxifene therapy falls within the same range of risk due to 
estrogen-progestin therapy. The magnitude is similar.68 In 
the RUTH trial, raloxifene was associated with an increased 
risk of fatal stroke (HR 1.49) and venous thromboembolism 
(HR 1.44).48 In the STAR trial, the risk for venous thrombo-
embolic events (pulmonary emboli and deep vein thromboses) International Journal of Women’s Health 2009:1 16
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is less with raloxifene versus tamoxifen, and the numbers of 
strokes and transient ischemic attacks that occurred in both 
groups were statistically equivalent.63,64
A recent meta-analysis to evaluate the effect of raloxifene 
on the risk of deep vein thrombosis and pulmonary embolism 
showed that therapy with raloxifene was associated with a 
62% increase in the odds (odds ratio 1.62, p  0.001),81 
although raloxifene is probably not associated with an 
increased risk of arterial thromboembolism.82
Others
Hot ﬂ  ushes, leg cramps, and peripheral edema are all known 
to be associated with raloxifene use, but the only signiﬁ  cant 
adverse effect of therapy was hot ﬂ  ashes (25% versus 18% 
in the placebo group); hot ﬂ  ashes were typically reported 
as mild and were not associated with study withdrawal 
(1.7% versus 2.4% for placebo).42 In the MORE and CORE 
experience, the higher frequency versus placebo of hot ﬂ  ashes 
(12.5% versus 6.9%), cramps of the lower limbs (14.9% ver-
sus 11.8%), and ﬂ  uid retention may be a reason for halting 
raloxifene use in menopausal women.43,61
Raloxifene did not increase the risk of all non-breast 
cancers, including endometrial cancer. The higher incidence 
of reported gallbladder disease was not conﬁ  rmed.79 The inci-
dence of cataracts in the raloxifene group is similar to that seen 
for the general population.63,64 The prevalence of low BMD 
and osteoporosis increases with greater severity of chronic 
kidney disease, and raloxifene is safe and effective for post-
menopausal women affected by chronic kidney disease.83
New perspectives
New third-generation SERMs are expected to demonstrate 
anti-fracture efﬁ  cacy at the hip level, with extra-skeletal 
beneﬁ  ts, but without adverse effects associated with current 
therapies. Third-generation investigational SERMs include 
idoxifene, droloxifene, ospemifene,84 arzoxifene, acolbifene, 
levormeloxifene, lasofoxifene, and bazedoxifene.85
In particular, lasofoxifene selectively binds to ER with 
high afﬁ  nity and it has a half-inhibition concentration similar 
to that seen with estradiol and thus at least 10-fold higher 
than those reported for raloxifene and tamoxifen. Moreover, 
due to increased resistance to intestinal wall glucuronidation, 
lasofoxifene has a markedly improved oral bioavailability with 
respect to other SERMs. In preclinical and short-term clinical 
studies lasofoxifene has shown a proven efﬁ  cacy in preventing 
bone loss and lowering cholesterol levels. Dose modeling 
from phase II studies allowed the selection of lasofoxifene 
0.25 mg/day as the lowest fully effective dose.86
The phase III program includes two completed identical, 
placebo-controlled, 2-year studies (Osteoporosis Prevention 
and Lipid Lowering [OPAL]), an ongoing fracture 
trial (PEARL) and a comparative trial with raloxifene 
(CORAL).87 The aim is to ﬁ  nd a compound with the ideal 
proﬁ  le, that is, the alleviation of climacteric symptoms 
and the prevention of osteoporotic fractures, but with-
out any adverse effects on the breast and endometrium, 
and no negative effects or even beneﬁ  cial effects on the 
cardiovascular system and the brain.88,89 In a 2-year phase 
III study, bazedoxifene prevented bone loss, reduced bone 
turnover, and was well tolerated in early postmenopausal 
women with normal or low BMD.90
Moreover, combination therapy of old and new-generation 
SERMs with different drugs may be another area of potential 
development. For example, a recent small population trial has 
shown signiﬁ  cant beneﬁ  ts for climacteric symptom control 
with the addition of low-dose esteriﬁ  ed conjugated estro-
gens to standard doses of raloxifene.91 The ability of future 
SERMs to exert estrogenic agonistic/antagonistic activity in 
a tissue-speciﬁ  c manner may allow these agents to improve 
bone health while protecting uterine and breast tissue. The 
combination of a SERM and low-dose estrogen could protect 
bone, alleviate menopausal symptoms, and improve lipid 
proﬁ  le without stimulating proliferation of uterine and breast 
tissue, which could represent a viable alternative for the treat-
ment of younger menopausal women. Controlled clinical trial 
data will be needed to conﬁ  rm these effects.92
Compliance to therapy
Adherence to osteoporosis medications is relatively poor: 
approximately 20% to 30% of patients taking daily or 
weekly treatments may suspend their treatment within 6 to 
12 months of initiating therapy. The majority of patients 
who discontinue therapy appear to do so because of drug-
induced adverse effects and fear of health risks,93 although 
withdrawals due to any reason (37%) and withdrawals due 
to adverse events (14%) were not different versus placebo.42 
In addition, Asian women showed a greater propensity to 
remain on raloxifene, compared with bisphosphonates, and 
the women on raloxifene exhibited lower discontinuation 
rates and higher treatment satisfaction, which addressed the 
more favorable compliance and tolerance with raloxifene 
than with bisphosphonates.94 Postmenopausal women 
with osteoporosis, who have poor compliance when tak-
ing alendronate, can be switched to raloxifene, because 
they can still see beneﬁ  ts in BMD and bone turnover 
with raloxifene after discontinuing alendronate therapy.95 International Journal of Women’s Health 2009:1 17
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Moreover, the CORAL multicenter study showed very 
good patient compliance with raloxifene for treatment 
satisfaction, health condition, and quality of life; prema-
ture discontinuation of therapy was observed in a very low 
number of women.96
Summary and conclusion
Raloxifene is effective to prevent and treat postmenopausal 
vertebral osteoporosis, with reduction of spine fractures and, 
in post-hoc analyses, non-spine fractures in high-risk subjects. 
This efﬁ  cacy is conﬁ  rmed by evidence that raloxifene shows 
a low number needed to treat (ie, the number of patients to 
be treated to avoid one radiological vertebral fracture over 
the duration of the study): range 28 to 31 versus 15 to 64 for 
alendronate and 8 to 26 for risedronate.97
A global index of clinical outcomes, deﬁ  ned as described 
for the Women’s Health Initiative (WHI) trial (the earliest 
occurrence of coronary heart disease, stroke, pulmonary 
embolism, invasive breast cancer, endometrial cancer, 
colorectal cancer, hip fracture, or death because of other 
causes) was applied to the MORE trial data.19 The signiﬁ  cant 
25% reduction in global index (150 fewer events per 10,000 
women taking raloxifene for an average of 3.4 years) is 
compatible with a favorable risk-beneﬁ  t safety proﬁ  le when 
raloxifene is used for osteoporosis treatment in postmeno-
pausal women.98 Moreover, raloxifene reduces the risk of 
breast cancer and improves the levels of serum lipoprotein, 
with a favorable risk-beneﬁ  t proﬁ  le against an increased risk 
of venous thromboembolism and fatal stroke, but without 
signiﬁ  cant change in the incidence of coronary events.
Table 1 “Over 1000 participants” trials with raloxifene (60 mg/day)
Trial Population Duration Efﬁ  cacy Safety
Johnston et al42 1,145 3 years Spine, hip and total body BMD 
preservation in healthy women
Tolerability proﬁ  le comparable to placebo
MORE43,44 7,705 4 years Cumulative risk of new vertebral 
fractures, absolute number and 
severity, reduction in osteoporotic 
women. No effect on non-vertebral 
fracture risk (reduction in post 
hoc analysis of patients with severe 
prevalent vertebral fractures)
Venous thromboembolism risk increase.
ER+ invasive breast cancer risk 
reduction. No effect on cardiovascular 
events, stroke, endometrial cancer and 
hyperplasia
CORE47,60 4,011 4 years Lumbar spine and femoral neck 
BMD increase in MORE population.
No effect on non-vertebral fracture 
risk (reduction in post hoc analysis 
of patients with severe prevalent 
vertebral fractures)
Venous thromboembolism risk increase.
ER+ invasive breast cancer risk 
reduction. No effect on cardiovascular 
events, stroke, endometrial cancer and 
hyperplasia
RUTH48 10,101 5.6 years Clinical vertebral fracture 
risk reduction in older women 
with or at increased risk for coronary 
heart disease. No effect on 
non-vertebral fracture risk
Venous thromboembolism risk and fatal 
stroke increase. ER+ invasive breast 
cancer risk reduction. No effect on 
coronary heart disease
STAR62,63 19,747 5 years No statistical different rates of 
fracture in raloxifene and tamoxifen 
arms in women at increased risk for 
invasive breast cancer
Raloxifene as effective as tamoxifen in 
ER+ invasive breast cancer risk reduction.
Less venous thromboembolism and 
uterine cancer risk for raloxifene versus 
tamoxifen. No difference in strokes and 
cardiovascular events in raloxifen and 
tamoxifen arms
EVA50,51 1,412 1.5 years No statistical difference in fracture 
risk in raloxifene and alendronate 
arms (greater BMD increase with 
alendronate)
Venous thromboembolism risk 
increase with raloxifene versus 
gastrointestinal problems risk increase 
with alendronate
CORAL99 1,497 1.5 years High compliance No signiﬁ  cant discontinuation of therapy 
for adverse events
Abbreviations: MORE, Multiple Outcomes Raloxifene Evaluation; CORE, Continuing Outcomes Relevant to Evista; RUTH, Raloxifene Use for The Heart; STAR, Study of 
TAmoxifen and Raloxifene; EVA, EVista Alendronate comparison; CORAL, COmpliance with RALoxifene therapy.International Journal of Women’s Health 2009:1 18
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On the basis of evidence of MORE, CORE, RUTH, 
and STAR trials, in September 2007, the FDA approved 
raloxifene hydrochloride tablets for reduction in the risk 
of invasive breast cancer in postmenopausal women with 
osteoporosis and in postmenopausal women at high risk for 
invasive breast cancer. The reduction in incidence of breast 
cancer was primarily due to a reduction in the incidence 
of ER-positive invasive breast cancers. There was no 
reduction in ER-negative invasive breast cancers, and there 
was no difference in incidence of non-invasive breast cancers 
between the raloxifene and placebo groups.
Raloxifene is associated with an increased risk of deep 
vein thrombosis, pulmonary embolism, and retinal vein 
thrombosis. An increased risk of death due to stroke was 
observed in a trial in postmenopausal women with documented 
coronary heart disease or at increased risk for major coronary 
events. Each individual postmenopausal woman’s risk/beneﬁ  t 
ratio must be carefully considered. Women should be aware that 
raloxifene does not completely prevent breast cancer and that 
regular mammograms and breast examinations are essential.99
However, some points of criticism derive from limita-
tions in determining skeletal endpoints in many trials. In fact, 
the measurement of BMD depends on several parameters 
and if the variations also in the same patient are not fully 
comparable, then BMD decrease does not always indicate 
treatment failure. Moreover, the degree of adherence to 
therapy, close follow-up and no identiﬁ  able secondary cause 
of osteoporosis are all parameters difﬁ  cult to evaluate in large 
randomized controlled trials, even if well conducted.
With an understanding of the risk-benefit ratio and 
head-to-head comparisons of different drugs, it may be 
easier to prescribe an appropriate drug in postmenopausal 
women with osteoporosis, and data from ongoing trials 
will enhance our understanding of the risks and beneﬁ  ts of 
raloxifene across multiple diseases that can affect the health 
of postmenopausal women.100
The evidence derived from the literature (Table 1) 
suggests that the overall risk-beneﬁ  t ratio of raloxifene is 
favorable, and the drug is approved widely for the prevention 
and treatment of postmenopausal osteoporosis.42,98,101 In 
particular, raloxifene, an example of a multifunctional drug,102 
offers the best beneﬁ  ts for a speciﬁ  c population climacteric 
symptom-free postmenopausal women who need osteoporosis 
therapy, fracture and breast cancer prevention, but at a low 
risk of venous thromboembolism.100
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